Jeffrey Tate - Cyclo Therapeutics Chief COO
| CYTHW Stock | USD 0.14 0.04 22.22% |
Insider
Jeffrey Tate is Chief COO of Cyclo Therapeutics
| Age | 66 |
| Address | 6714 NW 16th Street, Gainesville, FL, United States, 32653 |
| Phone | 386 418 8060 |
| Web | https://cyclotherapeutics.com |
Cyclo Therapeutics Management Efficiency
The company has return on total asset (ROA) of (2.8249) % which means that it has lost $2.8249 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (226.6391) %, meaning that it generated substantial loss on money invested by shareholders. Cyclo Therapeutics' management efficiency ratios could be used to measure how well Cyclo Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to -1.44 in 2024. Return On Capital Employed is likely to drop to -4.4 in 2024. At this time, Cyclo Therapeutics' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to climb to about 2.8 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 36.4 K in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Michael Hargis | GoHealth | 52 | |
| Jason BSc | QBE Insurance Group | 56 | |
| Melissa Balsan | GoHealth | N/A | |
| Matt MBA | QBE Insurance Group | N/A | |
| Vijay Kotte | GoHealth | 46 | |
| Samuel BA | QBE Insurance Group | 53 | |
| Clinton Jones | GoHealth | 46 | |
| Glen FCMA | BCE Inc | 56 | |
| Jay Sreedharan | GoHealth | N/A | |
| John Mutschink | Employers Holdings | 51 | |
| Shane Cruz | GoHealth | 44 | |
| BA ACA | QBE Insurance Group | N/A | |
| Todd Waletzki | Asure Software | N/A | |
| Toshio Uchida | Palomar Holdings | 50 | |
| Jonathan Knutzen | Palomar Holdings | 52 | |
| Cheryl Trbula | Asure Software | N/A | |
| Ashley Dalziell | QBE Insurance Group | N/A | |
| McDonald Armstrong | Palomar Holdings | N/A | |
| Dennis Dix | Employers Holdings | N/A | |
| Jon Christianson | Palomar Holdings | 44 | |
| Robert Malcolmson | BCE Inc | N/A | |
Management Performance
| Return On Equity | -226.64 | ||||
| Return On Asset | -2.82 |
Cyclo Therapeutics Leadership Team
Elected by the shareholders, the Cyclo Therapeutics' board of directors comprises two types of representatives: Cyclo Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cyclo. The board's role is to monitor Cyclo Therapeutics' management team and ensure that shareholders' interests are well served. Cyclo Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cyclo Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Lisjak, Global Development | ||
| George Fails, Ex Mang | ||
| Jeffrey Tate, Chief COO | ||
| Scott Fine, CEO Director | ||
| Lori McKenna, Global Advocacy | ||
| Joshua Fine, CFO Secretary | ||
| E Strattan, Founder Director | ||
| Sharon Hrynkow, VP Officer | ||
| Lori Gorski, Global Advocacy | ||
| Karen FFPM, Interim Officer |
Cyclo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cyclo Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Cyclo Stock Analysis
When running Cyclo Therapeutics' price analysis, check to measure Cyclo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclo Therapeutics is operating at the current time. Most of Cyclo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cyclo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclo Therapeutics' price. Additionally, you may evaluate how the addition of Cyclo Therapeutics to your portfolios can decrease your overall portfolio volatility.